The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

David M. Livermore

Antibiotic Resistance Monitoring & Reference Laboratory

Health Protection Agency Microbiology Services-Colindale

61 Colindale Avenue

London NW9 5EQ



Name/email consistency: high



  • Antibiotic Resistance Monitoring & Reference Laboratory, Health Protection Agency Microbiology Services-Colindale, 61 Colindale Avenue, London NW9 5EQ, UK. 2011
  • Antibiotic Resistance Monitoring & Reference Laboratory, HPA Centre for Infections, London, United Kingdom. 2003 - 2011


  1. Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae. Livermore, D.M., Mushtaq, S., Nguyen, T., Warner, M. Int. J. Antimicrob. Agents (2011) [Pubmed]
  2. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Livermore, D.M., Warner, M., Mushtaq, S., Doumith, M., Zhang, J., Woodford, N. Int. J. Antimicrob. Agents (2011) [Pubmed]
  3. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae. Livermore, D.M., Mushtaq, S., Warner, M., Zhang, J., Maharjan, S., Doumith, M., Woodford, N. Antimicrob. Agents Chemother. (2011) [Pubmed]
  4. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. Livermore, D.M., Mushtaq, S., Warner, M., Zhang, J.C., Maharjan, S., Doumith, M., Woodford, N. J. Antimicrob. Chemother. (2011) [Pubmed]
  5. Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms. Livermore, D.M., Mushtaq, S., Warner, M. J. Antimicrob. Chemother. (2010) [Pubmed]
  6. Antimicrobial treatment and clinical outcome for infections with carbapenem- and multiply-resistant Acinetobacter baumannii around London. Livermore, D.M., Hill, R.L., Thomson, H., Charlett, A., Turton, J.F., Pike, R., Patel, B.C., Manuel, R., Gillespie, S., Balakrishnan, I., Barrett, S.P., Cumberland, N., Twagira, M. Int. J. Antimicrob. Agents (2010) [Pubmed]
  7. Temocillin revived. Livermore, D.M., Tulkens, P.M. J. Antimicrob. Chemother. (2009) [Pubmed]
  8. Has the era of untreatable infections arrived? Livermore, D.M. J. Antimicrob. Chemother. (2009) [Pubmed]
  9. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. Livermore, D.M., Mushtaq, S., Warner, M., Woodford, N. J. Antimicrob. Chemother. (2009) [Pubmed]
  10. Doripenem: antimicrobial profile and clinical potential. Livermore, D.M. Diagn. Microbiol. Infect. Dis. (2009) [Pubmed]
  11. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Livermore, D.M., Mushtaq, S., Ge, Y., Warner, M. Int. J. Antimicrob. Agents (2009) [Pubmed]
  12. beta-Lactamases- the Threat Renews. Livermore, D.M. Curr. Protein Pept. Sci. (2009) [Pubmed]
  13. Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms. Livermore, D.M., Mushtaq, S., Warner, M. J. Antimicrob. Chemother. (2009) [Pubmed]
  14. Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers. Livermore, D.M., Hope, R., Mushtaq, S., Warner, M. Clin. Microbiol. Infect. (2008) [Pubmed]
  15. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06. Livermore, D.M., Hope, R., Brick, G., Lillie, M., Reynolds, R. J. Antimicrob. Chemother. (2008) [Pubmed]
  16. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. Livermore, D.M., Hope, R., Brick, G., Lillie, M., Reynolds, R. J. Antimicrob. Chemother. (2008) [Pubmed]
  17. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases. Livermore, D.M., Mushtaq, S., Warner, M., Miossec, C., Woodford, N. J. Antimicrob. Chemother. (2008) [Pubmed]
  18. Future directions with daptomycin. Livermore, D.M. J. Antimicrob. Chemother. (2008) [Pubmed]
  19. Defining an extended-spectrum beta-lactamase. Livermore, D.M. Clin. Microbiol. Infect. (2008) [Pubmed]
  20. Evaluation of the chromogenic Cica-beta-Test for detecting extended-spectrum, AmpC and metallo-beta-lactamases. Livermore, D.M., Warner, M., Mushtaq, S. J. Antimicrob. Chemother. (2007) [Pubmed]
  21. In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci. Livermore, D.M., Warner, M., Mushtaq, S., North, S., Woodford, N. Antimicrob. Agents Chemother. (2007) [Pubmed]
  22. Introduction: the challenge of multiresistance. Livermore, D.M. Int. J. Antimicrob. Agents (2007) [Pubmed]
  23. The zeitgeist of resistance. Livermore, D. J. Antimicrob. Chemother. (2007) [Pubmed]
  24. Antibiotic resistance: location, location, location. Livermore, D.M., Pearson, A. Clin. Microbiol. Infect. (2007) [Pubmed]
  25. CTX-M: changing the face of ESBLs in Europe. Livermore, D.M., Canton, R., Gniadkowski, M., Nordmann, P., Rossolini, G.M., Arlet, G., Ayala, J., Coque, T.M., Kern-Zdanowicz, I., Luzzaro, F., Poirel, L., Woodford, N. J. Antimicrob. Chemother. (2007) [Pubmed]
  26. Can beta-lactams be re-engineered to beat MRSA?. Livermore, D.M. Clin. Microbiol. Infect. (2006) [Pubmed]
  27. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Livermore, D.M., Woodford, N. Trends Microbiol. (2006) [Pubmed]
  28. Trends in penicillin and macrolide resistance among pneumococci in the UK and the Republic of Ireland in relation to antibiotic sales to pharmacies and dispensing doctors. Livermore, D.M., Reynolds, R., Stephens, P., Duckworth, G., Felmingham, D., Johnson, A.P., Murchan, S., Murphy, O., Gungabissoon, U., Waight, P., Pebody, R., Shackcloth, J., Warner, M., Williams, L., George, R.C. Int. J. Antimicrob. Agents (2006) [Pubmed]
  29. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. Livermore, D.M., Mushtaq, S., Warner, M. J. Antimicrob. Chemother. (2005) [Pubmed]
  30. Minimising antibiotic resistance. Livermore, D.M. Lancet. Infect. Dis (2005) [Pubmed]
  31. Tigecycline: what is it, and where should it be used?. Livermore, D.M. J. Antimicrob. Chemother. (2005) [Pubmed]
  32. Can better prescribing turn the tide of resistance?. Livermore, D. Nat. Rev. Microbiol. (2004) [Pubmed]
  33. The need for new antibiotics. Livermore, D.M. Clin. Microbiol. Infect. (2004) [Pubmed]
  34. In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles. Livermore, D.M., Mushtaq, S., James, D., Potz, N., Walker, R.A., Charlett, A., Warburton, F., Johnson, A.P., Warner, M., Henwood, C.J. Int. J. Antimicrob. Agents (2003) [Pubmed]
  35. The threat from the pink corner. Livermore, D.M. Ann. Med. (2003) [Pubmed]
  36. Properties and potential of ertapenem. Livermore, D.M., Sefton, A.M., Scott, G.M. J. Antimicrob. Chemother. (2003) [Pubmed]
  37. Ciprofloxacin-resistant Escherichia coli from bacteraemias in England; increasingly prevalent and mostly from men. Livermore, D.M., Nichols, T., Lamagni, T.L., Potz, N., Reynolds, R., Duckworth, G. J. Antimicrob. Chemother. (2003) [Pubmed]
WikiGenes - Universities